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Available online xxxxSclerostin is an osteocyte derived negative regulator of bone formation. A highly speciﬁc expression pattern and
the exclusive bone phenotype have made Sclerostin an attractive target for therapeutic intervention in treating
metabolic bone diseases such as osteoporosis and in facilitating fracture repair. Understanding the molecular
mechanisms that regulate Sclerostin transcription is of great interest as it may unveil new avenues for therapeu-
tic approaches. Such studies may also elucidate how various signaling pathways intersect to modulate boneme-
tabolism. Here we review the current understanding of the upstreammolecular mechanisms that regulate Sost/
SOST transcription, in bone.
© 2016 Published by Elsevier Inc.1. Introduction
Sclerostin, encoded by the SOST gene located on chromosome
17q12–21, is a 190-amino acid secreted glycoprotein that belongs to
the DAN family of bone morphogenetic protein (BMP) antagonists [1,
2]. Sclerostin is predominantly expressed by osteocytes and functions
as a negative regulator of bone formation [3]. In human, mutations in
the SOST gene locus are associated with sclerosteosis and Van Buchem
disease (VBD), two rare skeletal disorders characterized by excessive
bone growth [4,5]. Sclerosteosis is caused by loss of function mutations
in the SOST gene, resulting in undetectable levels of sclerostin in pa-
tients. Van Buchem patients carry a homozygous 52 kb noncoding dele-
tion that is essential for the transcriptional activation of SOST, which
leads to impaired sclerostin expression. Majority of sclerosteosis pa-
tients manifest a greater disease severity including gigantism and
hand abnormalities, possibly due to complete absence of sclerostin
compared to reduced sclerostin expression observed in VanBuchempa-
tients (Fig. 1) [6–10].
Sclerostin was originally identiﬁed as a BMP antagonist due to its
similarity to the DAN family of proteins and its ability to bind to BMPs
and inhibit BMP signaling [11]. However, later studies found a stronger
link between sclerostin and WNT signaling, classifying SOST as a nega-
tive regulator of WNT signaling [11,12]. The WNT signaling pathway is
an evolutionary conserved, intracellular signal transduction pathway
that regulatesmany cellular functions including cell proliferation, differ-
entiation,migration and stem cell maintenance [13]. TheWNT signaling
pathway is broadly classiﬁed as either canonical, which is a β-cateninDivision, Lawrence Livermore
CA 94550, USA.
G.G. Loots, Transcriptionaldependent pathway and non-canonical or β-catenin independent path-
ways [14]. In the canonical signaling pathway, WNTs signal through
seven trans-membrane domain receptor frizzled and single trans-mem-
brane co-receptors that belongs to the low-density lipoprotein family of
receptors (LRP5/6) and inhibit the destruction of cytoplasmic β-catenin
mediated by proteins such as adenomatous polyposis coli (APC), axin
and glycogen synthase kinase 3β (GSK3β). Stabilized β-catenin translo-
cates to the nucleus where it interacts with TCF/LEF family of transcrip-
tion factors and activates transcription of WNT-responsive genes. The
canonicalWNT signaling pathway is a major regulator of bone develop-
ment and metabolism. Gain of function mutations in WNT co-receptor
LRP5 have been detected in patients with high bone mass (HBM) phe-
notype [15,16] whereas patients with osteoporosis pseudoglioma syn-
drome carry loss of function mutations in LRP5 [17]. In mice,
osteoblast-speciﬁc deletion of both Lrp5 and Lrp6 resulted in signiﬁcant
reduction in bone mass [18]. Disruption of WNT expression [19–21] or
conditional deletion of β-catenin in osteoblasts/osteocytes [22,23] also
resulted in low bone mass. These ﬁndings underscore the importance
of canonical WNT signaling in regulating bone formation.
Sclerostin binds to LRP5/6 co-receptors and antagonizes canonical
WNT signaling [24–26] thereby inhibiting WNT signaling induced
bone formation [27]. Consistent with the human phenotype, targeted
deletion of Sost in mice resulted in increased bone formation and bone
strength; however, Sost knockout (Sost−/−) mice showed less than 5%
penetrance for syndactyly [28] and no facial distortion/palsy, two phe-
notypes commonly observed in sclerosteosis patients [29]. Transgenic
mice overexpressing Sost/SOST showed decreased bonemineral density,
bone volume and bone formation rate [11,30]. In vitro, sclerostin
inhibited osteogenic differentiation and mineralization of pre-osteo-
blastic cells and stimulated osteoblasts apoptosis [31,32]. Sclerostin
may also play a catabolic role in bone; it has been shown that sclerostincontrol of Sost in bone, Bone (2016), http://dx.doi.org/10.1016/
Fig. 1. Sclerosteosis and Van Buchemdisease. SOST locus (A). SOSTmutations associatedwith Sclerosteosis (B) and Van Buchemdisease (C). Patientwith sclerosteosis showing syndactyly
and facial distortion (D) (Adapted fromMoester et al. [6]). Lateral viewof the skull of a sclerosteosis patient showing extensive calvarial thickening (E) and anterior-posterior radiograph of
the hands with marked cortical hypertosis (F) (Adapted from Hamersma et al. [7]). Van Buchem patient with moderate craniofacial involvement, no syndactyly (G) (Adapted from
Beighton et al. [8]). Lateral view of the skull of an adult with Van Buchem disease, showing extensive sclerosis of the calvarium and the skull base (H) [Adapted from Van Hul et al. [9]).
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in osteocytes [33] and sclerostin antibody treatment decreased bone re-
sorption, in ovariectomized rats [34]. In line with this, several studies
have demonstrated that there is a signiﬁcant decrease in osteoclast sur-
face in mice lacking Sost [35,36].
Bouaziz et al. recently showed that sclerostin treatment inhibited
Wnt3a mediated JNK activation in chondrocytes, suggesting that SOST
may also play a role in non-canonicalWnt signaling [37]. Further studies
are required to understand the mechanism by which SOST regulate
non-canonical WNT signaling.
In a little over a decade following the discovery of sclerostin, many
advances have beenmade in understanding the role of sclerostin in reg-
ulating bone metabolism and sclerostin has emerged as a promising
therapeutic target for the treatment of bone disorders such as osteopo-
rosis. Human and animal studies with sclerostin monoclonal antibodies
have shown that antibody-mediated inhibition of sclerostin results in
signiﬁcant increases in bone mineral density [33,38]. As this protein
has a profound impact on the skeletal biology ﬁeld [6,39,40] under-
standing the molecular mechanisms that regulate sclerostin expression
is of great interest. It may also open up avenues for new therapeutic ap-
proaches. In this review, we will highlight the state of our current un-
derstanding of transcriptional regulation of sclerostin.
2. Sclerostin expression and tissue distribution
Due to its abundant expression in osteocytes and exclusive bone
phenotype [41], sclerostin is often described as a bone-speciﬁc protein.
However, several studies have shown that SOST has a broad expression
pattern (Fig. 2). Brunkow et al., using real-time quantitative PCR
(rtPCR), detected SOSTmRNA expression in whole long bone, cartilage,
kidney, liver, placenta and fetal skin [42]. Using semi-quantitative
rtPCR, they showed that Sost mRNA is expressed in several mouse
tissues including whole fetus, liver, heart, kidney, brain, thymus
and long bone [42]. Balemans et al. also showed SOSTmRNA expres-
sion in several human tissues including bone marrow, kidney, heart,Please cite this article as: A. Sebastian, G.G. Loots, Transcriptional
j.bone.2016.10.009lung, pancreas, skeletal muscle and osteoblast at day 21 [4]. In neo-
natal mice, using in situ hybridization, van Bezooijen et al. detected
Sost expression in the ascending aorta, aortic arch, brachiocephalic
artery, common carotids, and pulmonary trunk [43]. Recently,
using SostLacZ knock-in reporter mice, our group showed that Sost
mRNA is expressed in the heart, kidney, parts of the cerebellum, ep-
ididymis and vas deferens of the testis, the pyloric sphincter, and in
the ascending aorta branches [28] (Fig. 2). Several studies have de-
tected high expression of Sost in the kidney and a recent study by
Wang et al. suggests that lack of Sost may enhance renal ﬁbrogenic
response and promote the progression of renal interstitial ﬁbrosis,
in mice [44]. In bone, Sost is primarily expressed in osteocytes; how-
ever, low levels of Sostwere also detected in osteoblasts as well as in
osteoclasts [28] (Fig. 2).
Apart from osteocytes, sclerostin protein expression has also been
reported in several other tissues including mineralized hypertrophic
chondrocytes, odontoblasts and cementocytes [45–47]. Pederson et al.
[48] detected sclerostin mRNA and protein expression in early osteo-
clast precursors and found that sclerostin is rapidly down-regulated
during osteoclast differentiation. Sclerostin expression was also detect-
ed in the osteoclasts of agedmice [49]. Zhu et al. detected sclerostin up-
regulation during the vascular smoothmuscle calciﬁcation process [50].
It has been shown that joint trauma induces sclerostin expression in ar-
ticular cartilage and sclerostinmay protect against cartilage degradation
following joint injury [37,51]. Bouaziz et al., using destabilization of the
medial meniscus (DMM), a surgical model of osteoarthritis, showed
that loss of Sost increases cartilage damage in osteoarthritis mice [37].
Wehmeyer et al. recently showed that ﬁbroblast-like synoviocytes ex-
press SOST in a rheumatoid arthritis-like condition and the lack of
sclerostin or its antibody-mediated inhibition results in an acceleration
of the disease in a tumor necrosis factor alpha (TNFα) dependent man-
ner [52]. These studies suggest that sclerostin has a broader expression
pattern than originally estimated and that in addition to regulating bone
metabolism sclerostin may also play regulatory roles in other tissues
and cell types.control of Sost in bone, Bone (2016), http://dx.doi.org/10.1016/
Fig. 2. SOST expression in human and mouse tissues. SOST expression data from GNF Atlas 2 [109], Expression Atlas [110], Collette et al. [28], Brunkow et al. [42] and Balemans et al. [4]
showing tissue distribution of SOST (A). Sost expression in the E11.5 mouse embryo at the base of the spinal cord at the level of the forelimb (B) and by E12.5 consists of two distinct
domains (C). Sost expression in the mouse appendicular skeleton (D), axial skeleton (E, F), renal cortex (G), testis (H), distinct regions of the cerebellum (I), pyloric sphincter (J),
neonatal heart (K) and adult heart (L, M). Mouse long bone sections revealed Sost expression primarily in the osteocytes of cortical bone (N). Sost expression was also observed in the
multinucleated osteoclasts near trabecular bone in adult mice (O). Sost protein localizes in periosteal osteoblasts (green), which line the bone surface (P, white arrows). DAPI
counterstain indicates the location of cells (Q).m muscle; ocy osteocytes; bm bone marrow; po periosteum; and cb cortical bone. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Until recently, the majority of Sost/SOST expression studies have fo-
cused on its transcriptional regulation in cells along the osteoblast line-
age. In bone, several factors including hormones, growth factors and
cytokines regulate sclerostin transcriptionmainly via the proximal pro-
moter and the distal enhancer ECR5 [30]. Studies have shown that oste-
ogenic transcription factors RUNX2 and osterix (OSX/SP7) activate SOST
transcription via the proximal promoter [53–55]. Overexpression of
RUNX2 resulted in signiﬁcant increase in the SOST promoter activity,
in Saos-2 and MG63 osteoblastic cells [54]. OSX stimulated Sost expres-
sion in C2C12 cells and Osx−/−mice exhibited a signiﬁcant reduction of
Sost transcript [53]. In a recent study, Pérez-Campo et al. showed that
RUNX2 and OSX targets a region close to the SOST transcription start
site (TSS) and these two transcription factors have a cooperative effect
on SOST transcription, coordinately achieving signiﬁcantly higher SOST
promoter-reporter expression levels than those obtained with RUNX2
or OSX alone. They also identiﬁed a more distal, less active RUNX2 and
OSX responsive element in the promoter region, suggesting the exis-
tence of additional RUNX2 and OSX binding sites in the human SOST
promoter [55]. SOST promoter contains binding sites for several other
transcription factors including MYOD and CEBPB which may also play
a role in regulating SOST expression [54]. In a recent study, Fujiwara et
al. showed that a combination of four transcription factors: ATF3,
KLF4, PAX4, and SP7, efﬁciently induced SOST expression in human der-
mal ﬁbroblasts whereas IRF7 and MXI1 suppressed SOST transcription
[56]. However, it is not clear yetwhether these transcription factors reg-
ulate SOST expression directly or indirectly through other factors.
SOST transcription is also regulated via methylation of its proximal
promoter [57–59]; DNAmethylation may prevent binding of transcrip-
tion factors to the promoter thereby inhibiting SOST expression. In aPlease cite this article as: A. Sebastian, G.G. Loots, Transcriptional
j.bone.2016.10.009recent study, Delgado-Calle et al. showed that the SOST proximal pro-
moter is differentially methylated between human primary osteoblasts
and osteocytes [57]. The promoter regionwas hypermethylated in oste-
oblasts and hypomethylated in osteocytes. SOST expression was dra-
matically upregulated in osteoblasts treated with demethylating agent
AzadC [57]. In a subsequent study, they showed that inhibition of BMP
signaling blunted demethylating agent AzadC induced SOST expression
in human osteoblastic cells whereas treatmentwith recombinant BMP2
signiﬁcantly increased the transcriptional activity of the demethylated
SOST promoter [58]. BMP signaling has previously been identiﬁed as a
major regulator of SOST expression in osteogenic cells [60–63]. BMPs
promote Sost expression mainly via the Smad (Smad1/5/8) dependent
pathway [63]. Osteoblast-targeted conditional deletion of BMP receptor
type IA (Bmpr1a) in mice or blocking BMP signaling by adenovirus-me-
diated transfection of BMP inhibitor noggin resulted in signiﬁcant re-
duction of Sost expression whereas mice expressing constitutively
active Bmpr1a showed a signiﬁcant increase in Sost levels [61,63,64]. It
has been suggested that BMPs induce SOST expression mainly by
targeting the SOST promoter [58]; however, BMPs may also regulate
SOST expression independent of the SOST promoter [65].
The distal enhancer ECR5 is a 255-bp evolutionarily conserved se-
quencewithin the VBD deletion region. It has been shown that ECR5 en-
hances expression from both the human SOST and the heterologous
promoter (SV40) in UMR-106 osteoblasts [30]. Using ECR5LacZ reporter
mice it was showed that ECR5 is sufﬁcient to drive expression in osteo-
cytes; however, the SOST promoter was required for high levels of oste-
ocyte speciﬁc expression [36]. ECR5LacZ reporter mice expressed LacZ
throughout the skeleton [36]. Deletion of ECR5, inmice resulted in a sig-
niﬁcant reduction in Sost-positive osteocytes and a HBM similar to the
VBD phenotype, suggesting that ECR5 plays a prominent role in the os-
teocyte-speciﬁc regulation of Sost [36]. A response element for theMEF2control of Sost in bone, Bone (2016), http://dx.doi.org/10.1016/
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and subsequent mutation analysis determined that this MEF2 response
element is essential for the ECR5 enhancer activity [66]. In UMR-106
cells, siRNA-mediated knockdown of Mef2a,Mef2c, andMef2d resulted
in signiﬁcant reduction in Sost expression whereas Mef2b inhibition
had minimal effect on the endogenous Sost expression [66]. Among
the fourMef2 family transcription factors,Mef2c showed the highest ex-
pression in bone and in UMR-106 cells. Using immunohistochemistry,
we showed that MEF2 proteins co-localize with Sost in UMR-106 cells
and in mouse calvarial and femur osteocytes [66]. We also showed
that deletion of Mef2c selectively in the osteoblast/osteocyte lineage
cells in mice abolishes ECR5 reporter expression and results in HBM,
suggesting that MEF2C is a major regulator of ECR5 dependent Sost ex-
pression [36].
In a recent study, Wein et al. identiﬁed class IIa histone deacetylase
HDAC5 as a negative regulator of MEF2C driven Sost expression in oste-
ocytes [67]. In a novel murine osteocytic cell line Ocy454, shRNA-medi-
ated knockdown of HDAC5 increased Sost expression whereas HDAC5
overexpression decreased Sost levels. HDAC5 knockoutmice showed in-
creased levels of SostmRNA and signiﬁcantly more sclerostin positive
osteocytes. In osteocytes lacking HDAC5, Sost upregulation over time
was accompanied by increased MEF2C, H3K27ac (a mark associated
with active enhancers), and transcriptional co-activator p300 occupan-
cy at ECR5. Deletion of HDAC5 also resulted in decreased association of
co-repressors NCoR and HDAC3 with ECR5. Based on their ﬁndings,
Wein et al. proposed a model in which HDAC5, found in high levelsFig. 3. Current understanding of the transcriptional regulation of SOST: BMP signaling via Smad
context TGFβ signaling (via Smad2/3) either up-regulates SOST expression by acting through
expression in a HDAC5 and MEF2 dependent manner and this effect is mediated via ECR5
targeting the SOST promoter. TWEAK, IL-1α, IL-1β, calcitonin (CT) and retinoic acid (RA) up-
(CT-1) and leukemia inhibitory factor (LIF) down-regulate SOST. Vitamin D, glucocorticoid
dependent manner. SOST transcription is negatively regulated by mechanical loading, promote
transcription factors Runx2 and Sp7 bind to SOST promoter and activate SOST expression.
Please cite this article as: A. Sebastian, G.G. Loots, Transcriptional
j.bone.2016.10.009during early osteocyte differentiation, binds to ECR5 and subsequently
recruits the co-repressors HDAC3 and NCoR to block MEF2C-mediated
transcription of Sost. As osteocyte differentiation occur HDAC5 levels
fall which leads to increased MEF2C binding to ECR5 and recruitment
of transcriptional co-activator p300. This MEF2C/p300 binding leads to
enhancer activation and upregulation of Sost expression [67]. In con-
trast, siRNA-mediated knockdown of class I HDACs suppressed Sost ex-
pression in UMR-106 cells [68], suggesting that class I and IIa histone
deacetylases have opposite effects on Sost gene expression [68].
Parathyroid hormone (PTH) is a major negative regulator of Sost in
bone whose action is mediated via ECR5. Intermittent PTH administra-
tion increases bonemass by stimulating bone formation which is medi-
ated, at least in part, through the downregulation of Sost [69]. The
anabolic effect of PTH is blunted in Sost−/− deﬁcient mice as well as in
mice overexpressing SOST [70]. PTH suppressed Sost expression in
vitro and in vivo [71,72]. Transgenic mice expressing a constitutively ac-
tive PTH receptor exclusively in osteocytes exhibited increased bone
mass and reduced Sost expression [73]. Cyclic AMP (cAMP) inducer
forskolin inhibited Sost expression comparable to PTH, suggesting that
PTH-mediated suppression of Sost occurs mainly via the cAMP/PKA sig-
naling pathway [72]. PTH-mediated Sost inhibition was associated with
nuclear accumulation of the MEF2 inhibitor HDAC5 and binding to the
Sost enhancer ECR5, leading to inhibition of MEF2-mediated Sost en-
hancer activity [68]. This suggests that elevated sclerostin expression
observed in HDAC5−/− mice was at least in part due to impaired PTH
signaling [67]. However, it is not clear whether HDAC5 is necessary for1/5/8 increases SOST transcription by targeting SOST promoter. Depending on the cellular
ECR5 or down-regulates SOST transcription. Parathyroid hormone (PTH) inhibits SOST
. TNFα activates SOST expression possibly through a NFKB dependent mechanism, by
regulate SOST expression whereas PGE2, estrogen, oncostatin M (OSM), cardiotrophin-1
s (GC) and hypoxia (via HIF-1α) up- or down-regulate SOST expression in a context
r methylation (DNA-Met) and by epigenetic modiﬁcations induced by SIRT1. Zfp467 and
control of Sost in bone, Bone (2016), http://dx.doi.org/10.1016/
Table 1
Autocrine/paracrine regulators of SOST and their effect on SOST transcription.
Autocrine/paracrine
regulators Cell line/tissue
Sost
expression
BMP Human osteoblasts Up [60]
Mouse calvarial osteoblasts Up [61]
MLO-A5 Up [62]
Chondrocytes Up [59]
Saos-2 Up [65]
UMR-106 Up [83]
MC3T3 Up [74]
PTH UMR-106 Down [72]
Mouse calvariae Down [72]
Rat cortical bone Down [72]
MLO-A5 Down [71]
TGFβ UMR-106 Up [75]
MC3T3 Down [74]
Mouse primary osteoblasts Down [77]
Ocy454 Down [76]
PGE2 UMR-106 Down [83]
Saos-2 Down [84]
Ocy454 Down [76]
VitD Human osteocyte-like cells Up [85]
Human trabecular bone Up [85]
Mouse cortical bone Up [85]]
Saos-2 Up [85]
IDG-SW3 Down [86]
MC3T3 Down [74]
Retinoic acid MC3T3 Up [87]
Mouse primary calvarial osteoblasts Up [87]
Glucocorticoids Bone: mouse Up [89]
Serum: patients undergoing glucocorticoid
therapy
Up [88]
MC3T3 Down [74]
Plasma: Patients with endogenous
hypercortisolism
Down [90]
Estrogen Serum: patients undergoing estrogen
replacement therapy
Down [91]
Bone: ovariectomized mice Up [92]
Bone: ovariectomized mice Down [93]
IL-1α Chondrocytes Up [51]
IL-1β Osteocyte-enriched cells Up [97]
TNFα MLO-Y4 Up [99]
Mouse femur Up [92]
Human osteoblasts Up [98]
MG63 Up [98]
Synoviocytes Up [52]
TWEAK MC3T3 Up [98]
MLO-Y4 Up [98]
MG63 Up [98]
Human osteoblasts Up [98]
Oncostatin M Kusa 4b10 Down
[100]
UMR-106 Down
[100]
Mouse primary calvarial osteoblasts Down
[100]
Human primary osteoblast/osteocyte
cultures
Down
[100]
MC3T3 Down [74]
Cardiotrophin-1 UMR-106 Down
[100]
Leukemia inhibitory
factor
UMR-106 Down
[100]
Hypoxia UMR-106 Down
[101]
MC3T3 Up [102]
Saos-2 Up [56]
Sirtuin 1 C3H10T1/2 Down
[103]
Bone marrow-derived osteoblasts Down
[103]
Calcitonin Rat bone Up [106]
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HDAC5 had little effect on Sost promoter activity [66,68]. These data
demonstrated that PTH inhibits Sost expression through the MEF2 re-
sponse element in ECR5 and is independent of the Sost promoter [66].
Consistentwith theseﬁndings St John et al. showed that the suppressive
effects of cAMP inducer forskolin on Sost expressionwere abrogated fol-
lowing both ECR5 deletion and mutations in the MEF2 binding site in
ECR5 [74].
Transforming growth factor beta (TGFβ) pathway also regulates Sost
expression via ECR5. TGFβ family members TGFβ1, TGFβ2, TGFβ3 and
Activin A promote SostmRNA expression in UMR-106 cells [75]. Treat-
ment with SB431542, a TGFβ type I receptor antagonist inhibited Sost
expression [75]. siRNA-mediated inhibition of TGFβ type I receptors
Alk4 and Alk5 signiﬁcantly decreased endogenous Sost expression by
76% and 81%, respectively, while siRNA directed against another TGFβ
type I receptor, Alk7, only modestly changed Sost mRNA levels [75]. It
was shown that TGFβ1 induction of Sost involves Smad3; Smad3 inhib-
itor SIS3 attenuated endogenous and TGFβ-stimulated Sost expression.
Luciferase reporter assays indicated that TGFβ1 response depended on
the distal enhancer ECR5 rather than on the proximal promoter. Dele-
tion of the Smad binding site or MEF2C binding site in ECR5 prevented
TGFβ1 induced ECR5 reporter expression, suggesting that TGFβ stimu-
lates Sost expression through Smad and MEF2-dependent mechanisms
[75]. In contrast to these ﬁndings, St John et al. showed that TGFβ1 neg-
atively regulated SOST expression in MC3T3-E1 cells and this effect was
independent of ECR5 [74]. TGFβ also down-regulated Sost expression in
Ocy454 cells and inmature calvarial osteoblasts [76,77]. The phenotypic
differences between the cells used in these studies might have contrib-
uted to their differential response to TGFβ1 treatment and suggests that
the effect of TGFβ1 on Sost expression varies depending on the cellular
context.
Mechanical loading is a key regulator of SOST transcription in the
adult skeleton. Osteocytes aremechanosensitive cells. Mechanical stim-
ulation of bone results in dramatic reduction in Sost expression and a
corresponding increase in bone formation, while unloading results in
increased number of SOST positive osteocytes [78]. Furthermore,
Sost−/− mice did not lose bone mass after unloading [79] whereas
load induced bone formation was greatly reduced in transgenic mice
that constitutively express high levels of Sost [80]. These ﬁndings sug-
gest that mechanical loading regulates Sost expression and that load in-
duced bone formation is mediated, at least in part, through the down-
regulation of Sost. Nguyen et al. recently showed that TGFβ plays a crit-
ical role inmechanical loadingmediated regulation of Sclerostin expres-
sion [81]. They showed that loading repressed TGFβ signaling through
Smad2/3 and Sost expression. Furthermore, in DNTβRII mice that have
impaired TGFβ signaling due to expression of a dominant negative
TGFβ type II receptor under control of the osteocalcin promoter, the ap-
plication of mechanical load produced no distinguishable difference in
Sost expression, suggesting that loading regulates Sost via a TGFβ-de-
pendent mechanism. Consistent with previous ﬁndings [75], Nguyen
et al. also found that TGFβ rapidly induced Sost mRNA expression in
UMR-106 cells and treatment with TGFβ type I receptor inhibitor
SB431542 repressed Sost transcription. They also showed that co-
transfection with Smad3 was sufﬁcient to activate a promoter-re-
porter construct that expressed luciferase under the control of the
SOST promoter and 3 copies ECR5. However, Nguyen et al. found
that TGFβ-inducible SostmRNA expression was completely abrogat-
ed in the presence of cycloheximide, an inhibitor of translation,
even at a 2 h time point and they proposed that TGFβ-inducible
Sost expression occurs through an indirect Smad3-mediated path-
way [81].
Prostaglandin E2 (PGE2) is a mechanical loading induced secreted
soluble factor with a role in regulating bone metabolism. Mechanical
loading induces the expression of Cox2, the enzyme responsible for
PGE2 synthesis [82]. Recently, it was shown that PGE2 down-regulates
Sost expression in UMR-106 cells [83]. Knockdown of PGE2 receptorPlease cite this article as: A. Sebastian, G.G. Loots, Transcriptional
j.bone.2016.10.009EP2 (Ptger2), but not EP4 (Ptger4), signiﬁcantly impaired the ability of
PGE2 to suppress Sost expression. Also, EP2 agonist butaprostmimicked
the ability of PGE2 to decrease Sost, whereas EP4 agonist CAY10580 hadcontrol of Sost in bone, Bone (2016), http://dx.doi.org/10.1016/
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via an EP2-dependent mechanism, in UMR-106 cells [83]. However,
PGE2 failed to inhibit Sost expression in the presence of protein transla-
tion inhibitor cycloheximide indicating that PGE2 requires de novo pro-
tein synthesis to decrease Sost expression. In a different study, Galea et
al. [84] showed that, in human Saos-2 osteoblastic cells, PGE2 down-
regulates SOST expression in response to mechanical strain via an
EP4-dependent mechanism. Blockade of COX2 with the selective in-
hibitor NS398 and blockade of EP4 receptor with AH23848 both
prevented SOST down-regulation following mechanical strain
whereas blockade of EP2 receptor with AH6809 had no signiﬁcant ef-
fect on strain-induced SOST down-regulation. They also showed that
inhibition of mitogen activated protein kinase (MAPK)/ERK1/2
downstream of PGE2 with PD98059 prevented strain-induced
down-regulation of SOST and proposed that PGE2 down-regulates
SOST via an EP4/ERK-dependent mechanism. These differences sug-
gest that the mechanisms by which PGE2 regulates SOST expression
may be context dependent, and differ based on the inherent proper-
ties of the cells examined.
Steroids including vitamin D (VitD), retinoids, glucocorticoids and
sex steroids have also been shown to regulate SOST expression. VitD
alone or in combinationwith BMP4 signiﬁcantly enhanced SOST expres-
sion, in vitro [60,85]. VitD induced SOST expression is at least in partme-
diated by a putative VitD response element (VDRE) located ~6.2
kilobases (kb) upstream of the TSS [85]. However, in mouse derived
IDG-SW3 cells, VitD suppressed Sost expression [86]. Treatment with
retinoic acid up-regulated sclerostin mRNA and protein levels in
mouse calvarial osteoblasts and in MC3T3 cells [87], and enhanced
BMP-induced SOST expression, in human osteoblastic cells [60]. Elevat-
ed sclerostin levels have been reported in patients undergoing glucocor-
ticoid therapy [88] and treatment with glucocorticoids resulted in
increased Sost expression, in vivo [89]. Contrary to these ﬁndings, van
Lierop et al. showed that plasma sclerostin levels are signiﬁcantly de-
creased in patients with endogenous hypercortisolism or Cushing Syn-
drome [90]. Sex steroids estrogens and androgens protect against
bone loss. Estrogen replacement therapy reduced serum sclerostin
levels in humans [91]. Kim et al. reported that sclerostin expression in
the bone was stimulated by estrogen deﬁciency and it was reversed
by estradiol treatment [92]; however, Jastrzebski et al. found reduced
sclerostin expression in ovariectomized mice [93]. In male mice,
deletion of the androgen receptor made the mice more susceptible to
loading induced inhibition of sclerostin [94]. Treatment with dihydro-
testosterone (DHT) decreased sclerostin expression in cultured osteo-
cytes [95]; however, testosterone treatment did not inhibit sclerostin
increases triggered by sex steroid deﬁciency [91]. Discrepancies ob-
served in these studies suggest that the effects of steroids on SOST ex-
pression may also vary based on the cellular context and experimental
conditions.
In addition to hormones and growth factors, cytokines also play a
major role in regulating Sost [96,97]. Pathak et al. showed that IL-1β
and a combination of IL-1β, IL-6, and TNFα treatment enhanced SOST
expression in osteocyte-enriched cells [97]. A recent study by Chan et
al. showed that IL-1α up-regulated Sost expression in the articular
chondrocytes [51]. Vincent et al. showed that proinﬂammatory cytokine
TWEAK alone, or in combinationwith TNFα induced SOST expression in
human osteoblasts [98]. TNFα also induced Sost expression in ﬁbro-
blast-like synoviocytes in a mouse model of rheumatoid arthritis [52].
Moreover, TNFα blocker prevented ovariectomy induced sclerostin ex-
pression [92]. Baek et al. showed that in MLO-Y4 osteocytes TNFα in-
duced Sost via a NFκB-dependent mechanism. Using chromatin
immunoprecipitation and luciferase reporter assays they demonstrated
that NFκB directly binds to the NF-κB binding elements on the Sost pro-
moter to stimulate Sost transcription [99]. TNF-α inducedMEF2 activity
in UMR-106 cells suggested that TNFαmay also stimulate the expres-
sion of sclerostin viaMEF2-dependentmechanism [92].Walker et al. re-
cently showed that cytokines oncostatinM (OSM), cardiotrophin-1 (CT-Please cite this article as: A. Sebastian, G.G. Loots, Transcriptional
j.bone.2016.10.0091) and leukemia inhibitory factor (LIF) inhibited Sost expression via a
leukemia inhibitory factor receptor (LIFR) dependentmechanism [100].
Hypoxia is anothermajor regulator of Sost expression.We found that
in UMR-106 cells hypoxia decreased Sost expression and Smad1/5/8
phosphorylation, whereas hypoxia increased the expression of BMP an-
tagonists gremlin and noggin. This effect was mediated via HIF-1α
[101]. In contrast to these ﬁndings, Chen et al. found that in MC3T3 os-
teoblastic cells hypoxia induces Sost expression via a HIF-1α-dependent
mechanism [102]. Addition of DFO, a HIF-1α activator, further increased
Sost expression under hypoxia, whereas siRNA-mediated knockdown
HIF-1α resulted in down-regulation of Sost expression. Chen et al. also
showed that HIF-1α activates the Sost promoter activity in a dose-de-
pendent manner [102]. Fujiwara et al. showed that hypoxia induces
SOST expression in human Saos-2 cells. SOST expression was ~13 fold
upregulated in Saos-2 cells cultured under hypoxic condition for
3 days [56]. This difference in hypoxia-mediated regulation of Sost
may also arise from the phenotypic differences of the cell lines
employed in these experiments.
Other notable regulators of Sost include Sirtuin 1 (Sirt1), nitric oxide,
extracellular matrix protein periostin (POSTN), calcitonin and Zfp467.
Cohen-Kﬁr et al. identiﬁed Sirt1 as a potential negative regulator of
Sost expression, in the bone [103]. Using chromatin immunoprecipita-
tion analysis, they showed that Sirt1 negatively regulates Sost gene ex-
pression by deacetylating histone 3 at lysine 9 at the Sost promoter.
Nitric oxide and POSTN may play a role in mechanical load induced
down-regulation of Sost [104,105]. Calcitonin, a peptide hormone that
inhibits osteoclast activity, up-regulated sclerostin expression, in vivo
[106]. Zfp467 promotes Sost expression by physically interacting with
the Sost promoter [107]. Quach et al. showed that Zfp467 is down-reg-
ulated by PTH, OSM and CT-1 in the murine stromal osteoblastic cell
line Kusa 4b10, suggesting that Zfp467 may also play a role in PTH,
OSM and CT-1 mediated regulation of Sost [108].4. Concluding remarks
Targeting sclerostin seems to be an effective strategy for the treat-
ment of osteoporosis and other skeletal disorders, which makes
sclerostin a protein of great interest to skeletal biology ﬁeld. Identifying
the factors that regulate SOST expression and their mechanisms of ac-
tion will further our understanding of sclerostin biology and facilitate
the development of new therapies for treating bone disorders such as
osteoporosis. Several factors including hormones, growth factors and
cytokines have been identiﬁed as regulators of SOST expression. Many
of these factors regulate SOST expression via the proximal promotor or
the distal enhancer ECR5 (Fig. 3). However, recent studies suggest that
several factors including VitD, OSM and glucocorticoids regulate SOST
expression independent of the proximal promotor and ECR5, possibly
through other enhancers [74]. Techniques such as chromatin immuno-
precipitation coupled with massively parallel DNA sequencing (ChIP-
seq) should be employed to identify the novel candidate enhancer re-
gions that regulate SOST expression in response to these factors. Dis-
crepancies observed in the results published by different studies
suggest that SOST expression is tightly regulated in a context dependent
manner (Table 1). Including osteoblast lineage cells from various stages
of differentiation and origin in future studiesmaypossibly help us to ad-
dress these cellular context dependent differences in sclerostin
expression.Acknowledgement
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